2007: Clinical Osteoporosis and Metabolic Bone Disease I
Search or Browse by Day

Clinical Osteoporosis and Metabolic Bone Disease I

617
BMD Response to Teriparatide in Patients Previously Treated with a Bisphosphonate versus Treatment Naïve Patients
618
Reduction of Bone Turnover Markers with Annual Infusion of Zoledronic Acid 5 mg in Postmenopausal Osteoporosis: Influence of Age, Renal Function, Concomitant Therapy, and Duration of Treatment
619
The Effects of Zoledronic Acid 5 mg Once-Yearly on Bone Remodeling and Structure in Osteoporotic Women are Consistent Across Age
620
Relationship Between Annual Cumulative Exposure to Ibandronate, BMD Increases, and Clinical Fracture Reductions
621
Use of Ibandronate Results in Reduced Clinical and Nonvertebral Fracture Risk in Postmenopausal Osteoporosis
622
Monthly Ibandronate Use is Associated with Reduced Serious GI Event Risk Versus Weekly Bisphosphonates
623
Determinants of Femoral Neck Bone Loss in the HORIZON-PFT Study: Impact of Zoledronic Acid Therapy
624
Effects of Low Dose Corticosteroids on the Bone Mineral Density of Patients with Rheumatoid Arthritis: A Meta-Analysis
625
BMD Response to Teriparatide or Alendronate Therapy in Patients with Glucocorticoid-Induced Osteoporosis
626
Long-Term Prevention of Glucocorticoid-Induced Vertebral Fractures with Alendronate Versus Alfacalcidol: An Extension of the STOP-Study
627
The Direct Assessment of Non-vertebral Fracture in Community Experience (DANCE) Study: Baseline Demographics and Reasons for Initiating Teriparatide Therapy
628
Relative Importance of Dietary Calcium Intake and Serum 25-hydroxyvitamin D Status in Regard to Total Hip Bone Density Among Adults Age 20+
629
Impact of Poor Adherence to Bisphosphonates Therapy on Hip Fracture Risk in Osteoporotic Women
630
The Impact of GI Medication Usage with Regard to Discontinuation and Restart Behavior with Oral Bisphosphonates in Three Large US Physician Groups
631
Patient Knowledge and Beliefs about Osteoporosis: Factors Associated with Initiation of Treatment
632
Predictors of Bone Mineral Density (BMD) in a Large Cohort of Children with Juvenile Idiopathic Arthritis
633
Implementation of Guidelines for Osteoporosis and Fall Prevention in Patients with a Recent Clinical Fracture Reduces the Risk for New Clinical Fractures within One Year
634
Anti-TNF Treatment in Rheumatoid Arthritis Patients Does Not Alter the 1-year Change in Hand, Spine and Hip Bone Mineral Density Compared to Control Patients
635
Longitudinal Patterns in Bone Mass Measurement among U.S. Medicare Beneficiaries
636
Bisphosphonates Adherence and Fracture Risk: Time-Dependent Relationships from 103,038 Bisphosphonate Users in the US
637
Bone Turnover and Loss is Significantly Associated with Inflammatory Biomarkers in Older Adults: A Longitudinal Study
638
The Relationship Between Erosions and Osteoporosis in Rheumatoid Arthritis
639
Bone Mineral Density (BMD) Measured by Digital X-Ray Radiogrammetry (DXR) and Dual Energy X-ray Absorptiometry (DEXA) in Patients with Recent Onset Rheumatoid Arthritis (RA) after 1 Year of Treatment in the Best Study
640
Genetic Variation of XPD in Osteoporosis
See more of: ACR Abstract Submission Poster Sessions
<< Previous Session Level | Next Session Level >>